IHE: Misys trials open-source HIE platform

Misys successfully tested two open-source components needed to run a health information exchange (HIE) at the Integrating the Healthcare Enterprise (IHE) North America Connectathon in Chicago.

All the Misys Open Source Solutions (MOSS) software needed to exchange electronic files in a healthcare community will be made freely available in an open-source platform, according to the White Plains, N.Y.-based company.

Connectathon monitors reviewed and passed two core MOSS server side components of the IHE IT infrastructure profiles: MOSS' Cross Enterprise Document Sharing (XDS.b) with the Cross Community Access (XCA) profile (OpenXDS project) and its Audit Trail and Node Authentication - ATNA (OpenATNA project). These components, together with MOSS' patient identifier cross-referencing and patient demographics components, enable an exchange operator to identify a patient and exchange that patient’s clinical information, with their consent, across disparate systems, including hospitals, provider offices, labs and diagnostic centers in a community, the company said.

The HIE can be implemented in a decentralized manner or centrally depending on the specific requirements of the community, Misys stated. Any record requested is then tracked for auditing purposes.

Hartford Healthcare, of Hartford, Conn., provided assistance and collaboration to build out these IHE profiles, said Tim Elwell, vice president of MOSS. Hartford Healthcare will be the first recipient of this technology as it goes live in February, Elwell said.

The Misys Connect Exchange standards-based, open-source components may be downloaded at the Open Health Tools forge through the MOSS Web site, providing the capability for local communities to share patient records with the Nationwide Health Information Network (NHIN), according to the company.

The MOSS technology will be demonstrated in March at the Healthcare Information Management Systems & Society’s (HIMSS) 2010 Annual Conference and Exhibition in Atlanta, the company said.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.